Reevaluation by high-performance liquid chromatography: Clinical significance of microalbuminuria in individuals at high risk of cardiovascular disease in the Heart Outcomes Prevention Evaluation (HOPE) study

被引:25
|
作者
McQueen, Matthew J.
Gerstein, Hertzel C.
Pogue, Janice
Mann, Johannes F. E.
Yusuf, Salim
机构
[1] St Josephs Healthcare, Hamilton Reg Lab Med Program, Hamilton, ON L8N 4A6, Canada
[2] McMaster Univ, Populat Hlth Res Inst, Hamilton, ON, Canada
[3] Univ Munich, Schwabing Gen Hosp, Munich, Germany
关键词
microalbuminuria; cardiovascular risk; high-performance liquid chromatography; radioimmunoassay;
D O I
10.1053/j.ajkd.2006.09.003
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background In the Heart Outcomes Prevention Evaluation Study, microalbumin and albumin levels measured by using radioimmunoassay (RIA) and less than the microalbuminuria threshold in baseline urine samples were associated independently with cardiovascular (CV) events. Conventional immunoassays may underestimate albuminuria by not detecting a mildly denatured unfragmented form of albumin, immunounreactive to conventional antibodies. Methods: Microalbuminuria was reanalyzed in baseline samples stored at -70 degrees C for 5,358 North American participants, 1,992 with diabetes mellitus, by using a high-performance liquid chromatography (HPLC) system that also detects immunochemically nonreactive urinary albumin. Results:The HPLC compared with RIA method identified microalbuminuria in 1,585 versus 719 participants, 809 versus 423 patients with diabetes, by using a conventionally accepted albumin-creatinine ratio (ACR) of 29 mg/g or greater (>= 3 mg/mmol) as a cutoff value. HPLC-detected microalbuminuria increased risk for the primary outcome (a composite of myocardial infarction, stroke, and CV death); unadjusted hazard ratio, 1.85 (95% confidence interval, 1.57 to 2.19). Receiver operating characteristic analysis did not differentiate between HPLC- and RIA-detected microalbuminuria as predictors of CV outcomes. Conclusion: The prevalence of microalbuminuria is 2 to 3 times greater with HPLC than RIA using an ACR of 29 mg/g or greater ( :3 mg/mmol). The optimal cutoff value for detecting CV risk in the entire study population by means of RIA was 9 mg/g (0.9 mg/mmol), and with HPLC, 32 mg/g (3.4 mg/mmol). Results from this study also show different ACR cutoff values for individuals with diabetes: RIA, 13 mg/g or greater (>= 1.4 mg/mmol); HPLC, 44 mg/g or greater (>= 5.2 mg/mmol) and without diabetes: RIA, 7 mg/g or greater (>= 0.7 mg/mmol); HPLC, 29 mg/g or greater (>= 3/1 mg/mmol). Results highlight the importance of method-dependent cutoff values in the prediction of CV events.
引用
收藏
页码:889 / 896
页数:8
相关论文
共 50 条
  • [1] Impact of cigarette smoking in patients at high risk of cardiovascular disease. The heart outcomes prevention evaluation (HOPE) Study
    Dagenais, GR
    Yi, QL
    Yusuf, S
    [J]. CIRCULATION, 2002, 106 (19) : 666 - 666
  • [2] Prevalence and determinants of microalbuminuria in high-risk diabetic and nondiabetic patients in the heart outcomes prevention evaluation study
    Gerstein, HC
    Mann, JFE
    Pogue, J
    Dinneen, SF
    Hallé, JP
    Hoogwerf, B
    Joyce, C
    Rashkow, A
    Young, J
    Zinman, B
    Yusuf, S
    [J]. DIABETES CARE, 2000, 23 : B35 - B39
  • [3] Sensitive and high sensitivity cardiac troponin I concentrations in the Heart Outcomes Prevention Evaluation (HOPE) study - A high risk population
    Kavsak, Peter A.
    McQueen, Matthew J.
    [J]. CLINICA CHIMICA ACTA, 2010, 411 (21-22) : 1832 - 1832
  • [4] Cost implications of the use of ramipril in high-risk patients based on the Heart Outcomes Prevention Evaluation (HOPE) study
    Lamy, A
    Yusuf, S
    Pogue, J
    Gafni, A
    [J]. CIRCULATION, 2003, 107 (07) : 960 - 965
  • [5] Cost Effectiveness of Ramipril in Patients at High Risk for Cardiovascular EventsEconomic Evaluation of the HOPE (Heart Outcomes Prevention Evaluation) Study for Germany from the Statutory Health Insurance Perspective
    Peter K. Schädlich
    Josef Georg Brecht
    Badrudin Rangoonwala
    Eduard Huppertz
    [J]. PharmacoEconomics, 2004, 22 : 955 - 973
  • [6] Cost effectiveness of ramipril in patients at high risk for cardiovascular events -: Economic evaluation of the HOPE (Heart Outcomes Prevention Evaluation) study for Germany from the statutory health insurance perspective
    Schädlich, PK
    Brecht, JG
    Rangoonwala, B
    Huppertz, E
    [J]. PHARMACOECONOMICS, 2004, 22 (15) : 955 - 973
  • [7] Exploring New Models for Cardiovascular Risk Reduction: The Heart Outcomes Prevention and Evaluation 4 (HOPE 4) Canada Pilot Study
    Schwalm, Jon -David
    Mccready, Tara
    Lear, Scott A.
    Lamelas, Pablo
    Garis, Len
    Musa, Hadi
    Vincent, Kaitey
    Islam, Shofiqul
    Attaran, Amir
    Mckee, Martin
    Yusuf, Salim
    [J]. CJC OPEN, 2021, 3 (03) : 267 - 275
  • [8] Comparison and evaluation of a novel bioassay and high-performance liquid chromatography for the clinical measurement of serum voriconazole concentrations
    Steinmann, Joerg
    Huelsewede, Joerg
    Buer, Jan
    Rath, Peter-Michael
    [J]. MYCOSES, 2011, 54 (05) : E421 - E428
  • [9] Impact of cigarette smoking in high-risk patients participating in a clinical trial. A substudy from the Heart Outcomes Prevention Evaluation (HOPE) trial
    Dagenais, GR
    Yi, OL
    Lonn, E
    Sleight, P
    Ostergren, J
    Yusuf, S
    [J]. EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION, 2005, 12 (01): : 75 - 81
  • [10] Evaluation of Quality Control Methods for Foot-And-Mouth Disease Vaccines by High-Performance Liquid Chromatography
    Kim, Mun-Hyeon
    Yun, Seon-Jong
    Kim, Yeon-Hee
    Lee, Hyang-Sim
    Kim, Ji-Yeon
    Kim, Ji-Ye
    Kang, JeongWoo
    Kim, Yong-Sang
    Seo, Min-Goo
    [J]. PATHOGENS, 2020, 9 (03):